What to ask about treatment evidence

What to look for in a fair comparison

First identify the body part in the study, then the material used. Knee findings don't settle a shoulder question. A surgical add-on differs from a treatment performed alone at a clinic. Feeling better after care also doesn't prove that one choice beat another. Some human studies report better comfort or movement, while direct tests against other care remain mixed.

Animal findings can't predict the relief people will feel.

What to ask when the evidence is uncertain

Ask what improved, when it faded, and which other care served as comparison. Find out whether the difference was large enough for people to notice in daily life. QC Kinetix offers consultations where the licensed clinic team checks your joint and discusses non-surgical regenerative medicine choices, including blood-based care prepared for you. The medical team shouldn't promise more than the human evidence shows.

You can choose slowly when the likely benefit, cost, and recovery aren't clear.

Sources

1. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

2. A 2025 meta-analysis of 73 double-blind placebo-controlled injection trials in 5,895 knee osteoarthritis patients found placebo responder rates above 50 percent at 1, 3 and 6 months, declining by 12 months - which is why any uncontrolled 'our patients improved' claim from a clinic is uninterpretable.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Rev, 2025. DOI: 10.1530/EOR-2025-0022.

3. A 2024 systematic review of 8 Level I randomized trials in 937 patients found bone marrow aspirate concentrate improved pain and function versus baseline from one month, but the comparative advantage over other injections was inconsistent across timepoints.

   Han JH, et al. — Bone Marrow Aspirate Concentrate Injections for the Treatment of Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials. Orthop J Sports Med, 2024. DOI: 10.1177/23259671241296555.

4. A 2023 appraisal of 15 randomized and 11 non-randomized trials of culture-expanded MSCs for knee osteoarthritis found function improved relative to control in 11 of 15 RCTs and cartilage protection or repair reported in 18 of 21 imaging studies, but noted the total sample of 610 patients limits any definitive conclusion.

   Copp G, et al. — Culture-expanded mesenchymal stromal cell therapy: does it work in knee osteoarthritis? A pathway to clinical success. Cell Mol Immunol, 2023. DOI: 10.1038/s41423-023-01020-1.

5. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.

6. 21 CFR 1271.10(a) sets the four criteria a human cell or tissue product must meet to be regulated SOLELY under section 361 of the Public Health Service Act: it must be minimally manipulated; intended for homologous use only, as reflected by labeling and advertising; not combined with another article beyond water, crystalloids or a preserving agent; and either have no systemic effect and not depend on the metabolic activity of living cells, or else be for autologous use, use in a close blood relative, or reproductive use.

   US Code of Federal Regulations, Title 21 — 21 CFR 1271.10 - Are my HCT/P's regulated solely under section 361 of the PHS Act. , 2004.

7. In a Level I randomized trial of arthroscopic rotator cuff repair, augmenting the repair with concentrated bone marrow aspirate was compared against a sham incision with MRI assessment of structural healing at one year - the rare cell-therapy question asked with a proper blinded control.

   Cole BJ, et al. — Prospective Randomized Trial of Biologic Augmentation With Bone Marrow Aspirate Concentrate in Patients Undergoing Arthroscopic Rotator Cuff Repair. Am J Sports Med, 2023. DOI: 10.1177/03635465231154601.

8. A phase I single-arm study of 10 patients with chronic discogenic low back pain found a single intradiscal injection of adipose-derived MSCs with hyaluronic acid produced no procedure-related or cell-related adverse events over 12 months - a safety signal in 10 people, not an efficacy result.

   Kumar H, et al. — Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study. Stem Cell Res Ther, 2017. DOI: 10.1186/s13287-017-0710-3.

9. A randomized trial comparing commercially available systems in 71 patients found microfragmented adipose tissue equivalent to leukocyte-rich PRP on KOOS pain at 12 months.

   Baria M, et al. — Microfragmented Adipose Tissue Is Equivalent to Platelet-Rich Plasma for Knee Osteoarthritis at 12 Months Posttreatment: A Randomized Controlled Trial. Orthop J Sports Med, 2024. DOI: 10.1177/23259671241233916.